Stock listing
CLYM Stock Price, News, Filings & Events — Climb Bio, Inc.
Selected listing: CLYM · NASDAQ · USD · US
This page tracks Climb Bio, Inc.'s CLYM:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following CLYM:NASDAQ. CLYM:NASDAQ is the stock-level entry point for investors researching Climb Bio, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Climb Bio, Inc. (ticker: CLYM) is a public company based in America with a market capitalization of approximately $735.26 million. The company focuses on biotechnology and aims to develop innovative solutions in its field. Climb Bio is committed to advancing its research and development efforts to contribute to the healthcare industry.

- Ticker
- CLYM:NASDAQ
- Asset type
- Stock
- Market cap
- $818.5M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
Climb Bio, Inc. CLYM:NASDAQ stock context
This page tracks Climb Bio, Inc.'s CLYM:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following CLYM:NASDAQ. CLYM:NASDAQ is the stock-level entry point for investors researching Climb Bio, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Climb Bio, Inc. (ticker: CLYM) is a public company based in America with a market capitalization of approximately $735.26 million. The company focuses on biotechnology and aims to develop innovative solutions in its field. Climb Bio is committed to advancing its research and development efforts to contribute to the healthcare industry.
Latest news from Climb Bio, Inc.
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 6, 2026
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Cong...
June 11, 2026
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 20...
June 5, 2026
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
May 26, 2026
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
May 14, 2026
Research Climb Bio, Inc.
Climb Bio, Inc. investor report
Review AI stock analysis and investor report context for CLYM:NASDAQ.
Climb Bio, Inc. company profile
View the public company page for Climb Bio, Inc. on 6ix.
Climb Bio, Inc. news
Read company news and market updates connected to Climb Bio, Inc..
Climb Bio, Inc. investor events
Find investor webinars, events, and replay context for Climb Bio, Inc..